申请人:Nippon Kayaku Kabushiki Kaisha
公开号:EP0997462A1
公开(公告)日:2000-05-03
A novel naphthyridine compound represented by the general formula (1):
wherein R1, R2 and R3 are independently a hydrogen atom, a lower alkyl group or the like, or R1 and R2, or R2 and R3, when taken together, form a cyclic group; each of X and Y is a methylene or ethylene group; Z is a phenyl group, a substituted phenyl group or the like; A is a hydrogen atom, a lower alkyl group or the like; and G is an acyl group, shows antagonism for tachykinin receptors and is useful as a prophylactic or therapeutic agent for diseases for which the tachykinin receptors are considered to be responsible. A specific example of such a compound is 2-[(-)-4-(N-benzoyl-N-methyl)amino-3-(3,4-dichlorophenyl)butyl]-10-acetylamino-1,2,3,4-tetrahydro-benzo[b][1,6]naphthyridine.
一种通式(1)代表的新型萘啶化合物:
其中 R1、R2 和 R3 独立地为氢原子、低级烷基或类似基团,或 R1 和 R2 或 R2 和 R3 合在一起形成环状基团;X 和 Y 各为亚甲基或亚乙基;Z 为苯基、取代苯基或类似基团;A 是氢原子、低级烷基或类似基团;G 是酰基,显示出对速激肽受体的拮抗作用,可用作速激肽受体被认为是致病原因的疾病的预防或治疗剂。这种化合物的一个具体例子是 2-[(-)-4-(N-苯甲酰基-N-甲基)氨基-3-(3,4-二氯苯基)丁基]-10-乙酰氨基-1,2,3,4-四氢苯并[b][1,6]萘啶。